Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by various company officials on January 5, 2012. These acquisitions were executed at a price of 1,478.363 pence per share and resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share purchases under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,478.363 pence per Ordinary share on January 5, 2012.
- Confirm the total number of shares acquired by each listed director and manager.
- Review the terms of the GlaxoSmithKline ShareReward Plan to understand the dividend reinvestment mechanism.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.